Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.57 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247366 | 0.86 | ADAMTS5 (0.61) | ADAMTS5ADAMTS4L3MBTL1MMP2MMP8 | |
| SCHEMBL2250363 | 0.86 | L3MBTL1 (0.62) | ADAMTS5ADAMTS4LMNAL3MBTL1MMP2 | |
| SCHEMBL2244204 | 0.85 | L3MBTL1 (0.61) | ADAMTS5ADAMTS4L3MBTL1MMP2MMP8 | |
| SCHEMBL2249357 | 0.85 | NPC1 (0.67) | ADAMTS5ADAMTS4L3MBTL1MMP2MMP8 | |
| SCHEMBL2244966 | 0.84 | L3MBTL1 (0.60) | ADAMTS5ADAMTS4L3MBTL1MMP2MMP8 | |
| SCHEMBL2247187 | 0.84 | L3MBTL1 (0.60) | ADAMTS5ADAMTS4L3MBTL1MMP2MMP8 | |
| SCHEMBL2249268 | 0.84 | ADAMTS5 (0.58) | ADAMTS5ADAMTS4L3MBTL1MMP2MMP8 | |
| SCHEMBL2245265 | 0.84 | L3MBTL1 (0.72) | ADAMTS5ADAMTS4LMNAL3MBTL1MMP2 | |
| SCHEMBL2250028 | 0.83 | ADAMTS5 (0.57) | ADAMTS5ADAMTS4L3MBTL1MMP2MMP8 | |
| SCHEMBL2245808 | 0.83 | ADAMTS5 (0.57) | ADAMTS5ADAMTS4L3MBTL1MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | ADAMTS5 1/4885ADAMTS4 5/4885GAA 257/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | ADAMTS5 1/4885ADAMTS4 5/4885GAA 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.